MedTrace Logo

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00179660 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-01-21

Study results available
· View outcomes & findings →

Summary

To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.

Conditions

  • Non-Hodgkins Lymphoma

Interventions

DRUG

Lenalidomide

Capsules for oral administration.

Sponsors & Collaborators

  • Prologue Research International

    collaborator INDUSTRY

  • Celgene Corporation

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00179660 on ClinicalTrials.gov